Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a Cochrane Review and network meta‐analysis
Información
- DOI:
- https://doi.org/10.1002/14651858.CD013020Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 01 mayo 2018see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Protocol
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Urología
- Copyright:
-
- Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Yonas Mehari Tesfamariam: wrote the protocol.
Sascha Macherey: content input.
Kathrin Kuhr: methods input.
Ingrid Becker: methods input.
Ina Mosef: search strategy development.
Tina Jakob: wrote the protocol.
Axel Heidenreich: clinical expertise.
Nicole Skoetz: wrote the protocol.
Sources of support
Internal sources
-
No sources of support supplied
External sources
-
Federal Ministry for Education and Research (BMBF), Germany.
Grant no: 01KG1702
Declarations of interest
Yonas Mehari Tesfamariam: none known.
Sascha Macherey: none known.
Kathrin Kuhr: none known.
Ingrid Becker: none known.
Ina Monsef: none known.
Tina Jakob: none known.
Axel Heidenreich: none known.
Nicole Skoetz: none known.
Acknowledgements
We would like to thank members of Cochrane Urology for their comments and improving the review.
This project is funded by the Federal Ministry for Education and Research, grant no. 01KG1702.
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme.
Version history
| Published | Title | Stage | Authors | Version |
| 2020 Dec 03 | Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis | Review | Tina Jakob, Yonas Mehari Tesfamariam, Sascha Macherey, Kathrin Kuhr, Anne Adams, Ina Monsef, Axel Heidenreich, Nicole Skoetz | |
| 2018 May 01 | Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a Cochrane Review and network meta‐analysis | Protocol | Yonas Mehari Tesfamariam, Sascha Macherey, Kathrin Kuhr, Ingrid Becker, Ina Monsef, Tina Jakob, Axel Heidenreich, Nicole Skoetz | |
Notes
We have based parts of the Methods section of this protocol on a standard template developed by the Cochrane Metabolic and Endocrine Disorders Group, which has been modified and adapted for use by the Cochrane Urology Group. In addition, this protocol is partly based on suggested wording from the Pain, Palliative and Supportive Care Review Group (PaPaS CRG), the Cochrane Heamatological Malignancies Review Group and the protocol templates for a Cochrane intervention review that compares multiple interventions (Chaimani 2014; Chaimani 2017).
Keywords
MeSH
Medical Subject Headings (MeSH) Keywords
- Alendronate [adverse effects, therapeutic use];
- Antineoplastic Agents, Hormonal [therapeutic use];
- Bisphosphonate-Associated Osteonecrosis of the Jaw [etiology];
- Bone Density Conservation Agents [adverse effects, *therapeutic use];
- Bone Neoplasms [*drug therapy, *secondary];
- Clodronic Acid [adverse effects, therapeutic use];
- Denosumab [adverse effects, *therapeutic use];
- Diphosphonates [adverse effects, *therapeutic use];
- Etidronic Acid [adverse effects, therapeutic use];
- Network Meta-Analysis;
- Pamidronate [adverse effects, therapeutic use];
- Prostatic Neoplasms [drug therapy, *pathology];
- Prostatic Neoplasms, Castration-Resistant [pathology];
- Quality of Life;
- Randomized Controlled Trials as Topic;
- RANK Ligand [*antagonists & inhibitors];
- Risedronic Acid [adverse effects, therapeutic use];
- Zoledronic Acid [adverse effects, therapeutic use];
Medical Subject Headings Check Words
Adult; Humans; Male;
PICO
Direct and indirect comparisons of interventions (strength of line represents number of trials evaluating the comparison; dotted lines are indirect comparisons).
